1.38
+0.05000006(+3.76%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.31 |
| Day High | 1.42 |
| Day Low | 1.31 |
| 52-Week High | 4.01 |
| 52-Week Low | 0.36 |
| Volume | 2.03M |
| Average Volume | 3.72M |
| Market Cap | 229.78M |
| PE | -1.84 |
| EPS | -0.75 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 0.93 |
| Change | 0.05 |
If you invested $1000 in Tenaya Therapeutics, Inc. (TNYA) since IPO date, it would be worth $89.9 as of December 04, 2025 at a share price of $1.38. Whereas If you bought $1000 worth of Tenaya Therapeutics, Inc. (TNYA) shares 3 years ago, it would be worth $570.25 as of December 04, 2025 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Nov 08, 2025 4:25 PM GMT
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Co
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
GlobeNewswire Inc.
Nov 04, 2025 10:30 PM GMT
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking Presentation on Sunday to Showcase Results
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
GlobeNewswire Inc.
Oct 09, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlyi